AR and prostate cancer: While the proteome landscape between LNCaP cells, which feature a mutated AR, and LAPC4 cells utilized in the BioID experiments may be different, the relatively low number of essential genes among the AR proximity interaction landscape suggests that most candidates could be successfully targeted to modulate AR activity in PCa cells and suggests novel possibilities of treatment for prostate cancer patients.